※이 정보는 M투자그룹에서 생산한 것이 아닌 외부에서 얻은 정보를 공유하는 것입니다
※제공하는 정보는 투자판단의 참고자료이며, 투자판단의 최종책임은 본 정보를 열람하시는 이용자에게 있습니다
진원생명과학[011000]
이노비오 임상3상 인유두종바이러스(HPV) 면역치료제, 세계백신회의에서 ‘백신산업 최우수상’에 선정
Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress
April 17, 2019
PLYMOUTH MEETING, Pa., April 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as "Best Therapeutic Vaccine" at the World Vaccine Congress held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders.
http://ir.inovio.com/news-and-media/news/press-release-details/2019/Inovios-Phase-3-HPV-Immunotherapy-Selected-As-Best-Therapeutic-Vaccine-at-World-Vaccine-Congress/default.aspx
정보팀
2
0
0
